A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Primary Sjögrens Syndrome
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Primary Sjögrens Syndrome
The purpose of this study is to evaluate the efficacy of abatacept compared to placebo in patients with Sjögren's Syndrome.
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria could apply
Charlotte, North Carolina 28204, United States
Durham, North Carolina 27710, United States
Capital Federal, Buenos Aires 1015, Argentina
Ciudad Autonoma Beunos Aires, Buenos Aires 1431, Argentina
CABA, 1111, Argentina
Savaldor, Estado de Bahia 40150-150, Brazil
Kitakyushu-shi, Fukuoka 8078555, Japan
Nishinomiya-shi, Hyōgo 6638501, Japan
Kurashiki-shi, Okayama-ken 7108522, Japan
Chuo-ku, Tokyo 1048560, Japan
Itabashi-ku, Tokyo 1738610, Japan
Meguro-ku, Tokyo 1538515, Japan
Shinjuku-Ku, Tokyo 1608582, Japan
San Luis Potosí City, 78213, Mexico